Patients, caregivers and patient groups can share their experience and opinions with the BC Ministry of Health by filling out a Your Voice survey. See below for upcoming reviews by the Ministry of Health.
BC PharmaCare regularly reviews drugs to decide if they should cover the drug for people enrolled in BC PharmaCare plans. BC PharmaCare considers things like the drug’s safety, how well it works, and how expensive it is. Your input will help contribute to a better decision by BC PharmaCare on whether to cover a particular drug therapy. The window to provide your input is limited and listed below are reviews that will be coming soon with tentative dates when input will be accepted.
See: Your Voice – Province of British Columbia (gov.bc.ca) (https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/drug-coverage/drug-review-process-results/your-voice). Submit your input via the survey.
Upcoming Reviews with Your Voice Input
Therapeutic review of PharmaCare coverage for anticoagulant drugs used to treat cancer-associated thrombosis (CAT). The anticoagulant drugs included in our review are as follows:
Generic names: dalteparin, enoxaparin, enoxaparin biosimilars, tinzaparin, nadroparin, apixaban, rivaroxaban, dabigatran, edoxaban, and warfarin
Brand names: FRAGMIN®, LOVENOX®, LOVENOX HP®, NOROMBY™, REDESCA®, INCLUNOX®, INNOHEP®, FRAXIPARINE®, FRAXIPARINE Forte®, ELIQUIS®, XARELTO®, PRADAXA®, LIXIANA®, and warfarin
Drugs used for: the treatment of cancer-associated thrombosis (CAT)
Tentative Dates for Input: Wednesday, May 19, 2021 to Wednesday, June 16, 2021 AT MIDNIGHT
Ministry of Health will soon be considering the following drugs for PharmaCare coverage:
Generic name: upadacitinib
Brand name: Rinvoq™
Drug used for: the treatment of psoriatic arthritis in adults.
Tentative Dates for Input: From Wednesday, May 19, 2021 to Wednesday, June 16, 2021 AT MIDNIGHT
Ministry of Health will soon be considering the following drugs for PharmaCare coverage:
Generic name: elexacaftor/tezacaftor/ivacaftor and ivacaftor
Brand name: Trikafta®
Drug used for: the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Tentative Dates for Input: From Wednesday, May 19, 2021 to Wednesday, June 16, 2021 AT MIDNIGHT
Ministry of Health will soon be considering the following drugs for PharmaCare coverage:
Generic name: budesonide/ glycopyrronium /formoterol fumarate
Brand name: Breztri Aerosphere™
Drug used for: chronic obstructive pulmonary disease (COPD)
Tentative Dates for Input: From Wednesday, May 19, 2021 to Wednesday, June 16, 2021 AT MIDNIGHT
For help and resources in developing your submission to Your Voice or other stakeholder consultations with respect to fair and equitable access to medicines in BC, contact your respective patient organization (see our list of coalition members) or conatct Dr. Alan Low at MedAccessBC at alow@medaccessbc.org